Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Cell cycle progression protein S-phase checkpoint control protein" does not refer to a single, well-defined molecule but rather describes a functional category encompassing multiple proteins that regulate the S-phase DNA damage checkpoint during cell division. The S-phase checkpoint is part of the broader network of cell cycle checkpoints that monitor DNA integrity and replication status before allowing cells to proceed through critical phases such as DNA synthesis and mitosis. Key molecules involved in these checkpoints include cyclin-dependent kinases (CDKs), cyclins, tumor suppressors like p53, and sensor/effector kinases such as ATM/ATR, which collectively ensure proper replication and prevent propagation of damaged DNA[1][2][3]. Disruption or mutation in these pathways is strongly associated with cancer development due to loss of genomic stability. However, there is no canonical single "S-phase checkpoint control protein," making this entry non-specific and incorrect as a therapeutic target. The G1/S transition is governed by checkpoints involving multiple regulatory proteins including cyclins, CDKs, Rb family members, E2F transcription factors, ATM/ATR kinases, Chk1/Chk2 kinases, p21CIP/WAF1 inhibitors activated by p53—all acting together rather than via one unique "checkpoint control" molecule[1][2]. In summary: This entry does not correspond to any recognized individual therapeutic target but instead refers broadly—and imprecisely—to several key regulators within the complex machinery controlling cell division fidelity.
Not applicable; mechanisms depend on the specific molecular targets within the S-phase checkpoint pathway (e.g., CDKs, p53, ATM/ATR kinases).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell cycle progression protein S-phase checkpoint control protein.